PROGNOSTIC MARKERS FOR THE COVID-19 OUTCOMES AND ITS COMPLICATIONS IN PATIENTS WITH DIABETES MELLITUS

Abstract

Background. The prognosis of the development of complications of COVID-19 in patients with diabetes mellitus is of great practical interest.
Aim: to reveal prognostic markers for the COVID-19 outcomes and its complications in patients with diabetes mellitus
Material and methods: We analyzed data of 113 patients with type 2 diabetes who applied for hospitalization at the clinic of the Republican Specialized Scientific-and-Practical Centre of Endocrinology from March 2020 to December 2020. All patients were divided into 3 groups: the first group consisted of 31 patients who had a coronavirus infection within 1-3 days after hospitalization; the second group consisted of patients with documented COVID-19 - 52 people; and the third group consisted of 30 people without a history of coronavirus infection with a negative test for neutralizing antibodies to the SARS-CoV-2 virus.
Results: Fasting glycemia and postprandial glycemia were significantly higher in the group of people with acute COVID-19 in relation to persons who had not had a coronavirus infection, as well as in relation to persons who had a history of COVID-19, while significant differences in the level of glycated hemoglobin between groups was not observed, which can be explained by an acute inflammatory process in the 1st group of patients. the acute period of coronavirus infection is characterized by an increase in fasting and postprandial glycemia, the absence of leukocytosis, an increase in the level of ALT, GGT, C-reactive protein, fibrinogen, APTT, D-dimer, von Willebrand factor, ferritin, and interleukin 6. The post-COVID period in patients with type 2 diabetes is characterized by an increase in the level of AST, the perisistance of high levels of GGT, fibrinogen, D-dimer, von Willebrant factor, ferritin, procalcitonin and interleukin 6.
Conclusion: persistence of markers of inflammation after COVID-19 shows the necessity of thorough follow up of diabetes patients after recovery after COVID-19.